- Home
- OPTN vs ENTX Comparison
OPTN vs ENTX Comparison
Compare OPTN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- ENTX
- Stock Information
- Founded
- OPTN 2010
- ENTX 2010
- Country
- OPTN United States
- ENTX Israel
- Employees
- OPTN N/A
- ENTX N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPTN Health Care
- ENTX Health Care
- Exchange
- OPTN Nasdaq
- ENTX Nasdaq
- Market Cap
- OPTN 92.8M
- ENTX 101.3M
- IPO Year
- OPTN 2017
- ENTX 2018
- Fundamental
- Price
- OPTN $9.39
- ENTX $2.11
- Analyst Decision
- OPTN Hold
- ENTX Strong Buy
- Analyst Count
- OPTN 3
- ENTX 1
- Target Price
- OPTN $9.00
- ENTX $10.00
- AVG Volume (30 Days)
- OPTN 32.1K
- ENTX 43.0K
- Earning Date
- OPTN 05-20-2025
- ENTX 05-13-2025
- Dividend Yield
- OPTN N/A
- ENTX N/A
- EPS Growth
- OPTN N/A
- ENTX N/A
- EPS
- OPTN N/A
- ENTX N/A
- Revenue
- OPTN $78,226,000.00
- ENTX $181,000.00
- Revenue This Year
- OPTN $30.49
- ENTX N/A
- Revenue Next Year
- OPTN $13.51
- ENTX N/A
- P/E Ratio
- OPTN N/A
- ENTX N/A
- Revenue Growth
- OPTN 10.20
- ENTX N/A
- 52 Week Low
- OPTN $4.82
- ENTX $1.41
- 52 Week High
- OPTN $20.03
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- OPTN 76.14
- ENTX 52.23
- Support Level
- OPTN $9.37
- ENTX $2.08
- Resistance Level
- OPTN $9.45
- ENTX $2.41
- Average True Range (ATR)
- OPTN 0.08
- ENTX 0.19
- MACD
- OPTN -0.07
- ENTX -0.00
- Stochastic Oscillator
- OPTN 80.71
- ENTX 38.16
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.